查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2016908

結核病檢測市場：2026-2032年全球市場預測（依檢測類型、技術、檢體類型、最終用戶、通路和應用分類）

Tuberculosis Testing Market by Test Type, Technology, Sample Type, End User, Distribution Channel, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年結核病檢測市場價值為 23.5 億美元，預計到 2026 年將成長至 24.9 億美元，複合年成長率為 6.60%，到 2032 年將達到 36.8 億美元。

主要市場統計數據
基準年 2025 23.5億美元
預計年份：2026年 24.9億美元
預測年份 2032 36.8億美元
複合年成長率 (%) 6.60%

對當前結核病診斷趨勢進行全面概述，整合臨床實務、技術採用管道、供應鏈考量和採購重點。

本執行摘要整合了影響結核病診斷實務、技術應用和終端使用者優先事項的關鍵趨勢，涵蓋了整個臨床路徑。它從統一的觀點分析了診斷方法、監管變化、分銷趨勢以及影響檢查室、醫院和診所的不斷變化的營運壓力。本文著重強調了相關人員在供應鏈監管日益嚴格的情況下，如何協調採購、臨床工作流程和創新藍圖方面的實際意義。

技術融合、檢測分散化和不斷變化的臨床期望如何重塑醫療保健機構的診斷和營運重點。

由於分子技術的進步、體液檢體技術的創新以及照護現場（PoC）解決方案的加速發展，結核病診斷領域正經歷著變革性的轉變，這些解決方案顯著縮短了檢測結果的獲取時間。伴隨這些技術進步，臨床醫師的期望也在改變。他們越來越需要快速且可操作的檢測結果，以便指導即時的治療決策和接觸者追蹤干預措施。因此，診斷技術的發展方向正轉向兼顧靈敏度、操作便利性和快速出結果的平台。

關稅迫使供應鏈進行調整，策略採購政策轉變，重塑了我們診斷服務的採購行為、製造地和庫存彈性。

美國於2025年提高關稅，對全球診斷供應鏈造成了重大衝擊，尤其是結核病檢測流程中的關鍵組件和耗材。進口試劑、檢測套組和部分設備的關稅增加，提高了接收成本，也進一步凸顯了採購彈性的重要性。因此，檢查室和醫院的採購團隊紛紛審查供應商組合和合約條款，以減輕短期成本影響，並維持檢測的連續性。

透過整合的細分框架，將檢測方法、最終用戶需求、檢體物流和分銷管道連結起來，從而優先考慮臨床和商業策略。

了解市場區隔對於在整個結核病診斷過程中協調產品開發、商業化和臨床實施策略至關重要。在評估檢測類型時，相關人員需要區分培養檢測、免疫學檢測、分子診斷和快速診斷檢測。這些檢測方法中又包含重要的亞型，例如液體和固體培養方法、ELISA 和西方墨點法等免疫學檢測、分子診斷中的線性探針檢測和 PCR，以及快速診斷中的層析法和側向層析法。這些差異會影響檢測的處理能力、所需的技術技能以及與現有檢查室基礎設施的兼容性，從而指南在哪些領域投資自動化和培訓能夠帶來最大的營運回報。

區域監管協調、基礎設施多樣性和公共衛生優先事項如何推動世界各地不同的部署路線和供應策略。

區域趨勢既影響診斷技術的應用路徑，也影響醫療服務提供者面臨的營運挑戰。在美洲，各機構高度重視整合檢查室網路、確保檢測核准符合監管要求，並將診斷技術融入更廣泛的公共衛生舉措。這些優先事項正在影響採購計劃，並催生對檢驗、可互通且與現有實驗室資訊系統相容的解決方案的需求。

結合平台相容性、本地生產和整合服務的競爭策略和夥伴關係模式，以提高可靠性和部署能力。

結核病診斷領域的企業正透過產品改進、策略夥伴關係和業務拓展等一系列舉措，滿足不斷變化的臨床和供應鏈需求。成熟的診斷試劑製造商持續投資於儀器平台相容性、更廣泛的檢測範圍以及能夠降低醫院和檢查室客戶整體擁有成本的服務模式。同時，小規模但極具創新精神的企業則專注於提升特定領域的產品，例如改進檢體製備流程、提高側向層析檢測的靈敏度，以及提供可最大限度減少操作人員培訓的承包照護現場(PoC) 解決方案。

為領導企業提供切實可行的、優先的行動方案，以加強其供應鏈、加快替代檢驗，並使證據產生與醫療保健實踐的實際情況相符。

產業領導者應優先建立具有韌性的供應鏈，將短期風險緩解與長期策略協同結合。首先，透過供應商多元化和檢驗關鍵試劑和耗材的輔助訊息，降低對單一供應商的依賴。其次，加快合格和性能檢驗流程，以便在不造成不必要延誤的情況下引入替代供應商和本地生產線。這些營運措施應與強化合約保障和庫存策略相結合，以應對意外中斷。

透過結合與專家的初步訪談、供應鏈映射和監管趨勢的整合，我們透過高度透明和多方面的調查方法提供可操作和檢驗的見解。

本分析採用的研究途徑結合了多方面資料匹配、專家訪談和供應鏈圖譜分析，以確保獲得可靠的見解。主要定性資料是透過對臨床實驗室主任、醫院系統採購經理以及診斷設備製造商的高級研發和法規專家進行結構化訪談收集的，從而能夠客觀地了解營運重點和檢驗挑戰。這些洞見與最新的監管指導文件和同行評審文獻進行交叉比對，以檢驗臨床性能預期和技術權衡。

在技​​術和政策壓力不斷增加的情況下，我們必須將策略重點與營運要求相結合，以確保診斷的連續性、臨床準確性和可及性。

總之，結核病診斷領域正處於轉折點，技術進步、不斷變化的臨床需求以及貿易政策等外部壓力交織在一起，重塑採購和部署方案。積極調整產品策略以適應終端使用者工作流程、實現供應鏈多元化並投資於針對特定環境的實證研究的利益相關人員，將更有利於確保診斷的連續性並改善臨床療效。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依檢測類型分類的結核病檢測市場

  • 培養試驗
    • 液體培養
    • 固體的文化
  • 免疫學檢測
    • ELISA
    • 西方墨點法
  • 分子檢測
    • 線探針檢測
    • PCR
  • 快速診斷測試
    • 層析法
    • 側向流

第9章 結核病檢測市場：依技術分類

  • 培養方法
  • 免疫診斷
  • 脂多醣甘露聚醣測定
  • 核酸增幅檢查

第10章：結核病檢測市場－檢體類型

  • 血
  • 痰
  • 尿

第11章 結核病檢測市場：依最終用戶分類

  • 診所
  • 醫院
  • 測試機構

第12章 結核病檢測市場：依通路分類

  • 測試機構
  • 醫院藥房
  • 網路藥房

第13章 結核病檢測市場：依應用領域分類

  • 活動性肺結核
  • 潛伏性結核病

第14章 結核病檢測市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 結核病檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 結核病檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國結核病檢測市場

第18章：中國結核病檢測市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Becton Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Cepheid, Inc.
  • Hain Lifescience GmbH
  • QIAGEN NV
  • Roche Diagnostics International Ltd
  • Serum Institute of India
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
Product Code: MRR-03252A5F927A

The Tuberculosis Testing Market was valued at USD 2.35 billion in 2025 and is projected to grow to USD 2.49 billion in 2026, with a CAGR of 6.60%, reaching USD 3.68 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.35 billion
Estimated Year [2026] USD 2.49 billion
Forecast Year [2032] USD 3.68 billion
CAGR (%) 6.60%

Comprehensive orientation to current tuberculosis diagnostic dynamics integrating clinical practice, technology pathways, supply considerations, and procurement priorities

This executive summary synthesizes critical developments shaping tuberculosis diagnostic practices, technology adoption, and end-user priorities across clinical pathways. It provides an integrated view of diagnostic modalities, regulatory shifts, distribution dynamics, and evolving operational pressures affecting laboratories, hospitals, and clinics. The narrative purposefully emphasizes practical implications for stakeholders who must align procurement, clinical workflows, and innovation roadmaps under intensified supply chain scrutiny.

By grounding the analysis in recent regulatory updates, supply chain patterns, and clinical guidance, this overview equips clinical leaders and commercial strategists with clear context for decision-making. It distinguishes between diagnostic approaches by test type and technology, and it clarifies how sample type and end-user settings influence test selection and utilization. Ultimately, the introduction sets a foundation for targeted recommendations and operational actions that follow, enabling organizations to prioritize resilience, diagnostic accuracy, and patient-centered access in their tuberculosis testing strategies.

How technological convergence, decentralization of testing, and changing clinical expectations are reshaping diagnostics and operational priorities across care settings

The landscape for tuberculosis diagnostics is undergoing transformative shifts driven by advances in molecular techniques, fluid sample testing innovations, and the acceleration of point-of-care solutions that shorten time-to-result. These technical evolutions are accompanied by changing clinical expectations: clinicians increasingly expect rapid, actionable results that can guide immediate therapeutic decisions and contact tracing interventions. As a result, diagnostic development is moving toward platforms that balance sensitivity with operational simplicity and faster turnaround.

Concurrently, the diagnostic ecosystem is adapting to new distribution and access models that prioritize decentralized testing. Reference laboratories remain central for complex assays, while hospitals and clinics increasingly seek rapid diagnostic platforms that can be integrated into routine workflows. Technology convergence is also notable: culture-based approaches continue to be refined while nucleic acid amplification technologies and immunodiagnostic methods are being optimized for broader use across diverse care settings. These shifts demand strategic alignment across R&D, regulatory affairs, and commercial operations to ensure that novel diagnostics meet both clinical and logistical requirements.

Tariff-driven supply chain adaptations and strategic sourcing shifts that reshaped procurement behavior, manufacturing footprints, and inventory resilience in diagnostic services

The introduction of enhanced United States tariff measures in 2025 created material perturbations across global diagnostic supply chains, particularly for components and consumables critical to tuberculosis testing workflows. Tariffs on imported reagents, assay kits, and select instrumentation increased landed costs and amplified the importance of procurement agility. As a direct consequence, laboratories and hospital procurement teams revisited supplier portfolios and contractual terms to mitigate near-term cost impacts and to preserve test continuity.

In response, many organizations expanded localized sourcing strategies and accelerated qualification processes for alternative suppliers to reduce dependence on tariff-affected import routes. This pivot prompted a re-examination of inventory policies and a shift toward strategic stockholding for high-use consumables such as nucleic acid extraction kits and culture media. At the same time, manufacturers faced pressure to reassess their global production footprints, with several prioritizing regional manufacturing investments or contract manufacturing arrangements to circumvent tariff exposure. Regulatory pathways and supply validations became focal points, since alternate suppliers and newly localized production lines required timely but rigorous performance verification. Taken together, these adjustments underscore the need for resilient procurement practices, diversified supplier ecosystems, and integrated regulatory planning to navigate tariff-driven disruptions while maintaining diagnostic reliability and clinical continuity.

Integrated segmentation framework linking test modalities, end-user needs, sample logistics, and distribution channels to prioritize clinical and commercial strategies

Understanding segmentation is essential to align product development, commercialization, and clinical adoption strategies across the tuberculosis diagnostic continuum. When evaluating test types, stakeholders must differentiate among culture tests, immunological assays, molecular diagnostics, and rapid diagnostic tests; within these, there are important subtypes such as liquid and solid culture methods, ELISA and Western blot immunoassays, line probe assays and PCR within molecular testing, and chromatographic and lateral flow techniques among rapid diagnostics. These distinctions affect throughput, technical skill requirements, and compatibility with existing laboratory infrastructure, and they therefore guide where investments in automation and training will deliver the greatest operational returns.

End-user segmentation further refines prioritization because clinics, hospitals, and reference laboratories have divergent needs for turnaround time, batch processing, and complexity tolerance. Technology segmentation-spanning culture-based techniques, immunodiagnostics, lipoarabinomannan assays, and nucleic acid amplification tests-frames the product innovation pathway and regulatory strategy, as different technologies face distinct validation demands and clinical evidence thresholds. Sample type considerations, including blood, sputum, and urine, influence specimen collection logistics, biosafety protocols, and the suitability of point-of-care versus centralized testing. Distribution channel dynamics such as diagnostic laboratories, hospital pharmacies, and online pharmacy models shape procurement cycles and reimbursement touchpoints. Finally, application segmentation between active and latent tuberculosis demands different performance characteristics and interpretive frameworks. By integrating these segmentation layers, stakeholders can prioritize investments, define go-to-clinic deployment models, and tailor evidence generation to the settings and use cases that matter most.

How regional regulatory harmonization, infrastructure variability, and public health priorities drive differentiated adoption pathways and supply strategies across global regions

Regional dynamics influence both the adoption pathway of diagnostic technologies and the operational imperatives that providers face. Across the Americas, there is strong emphasis on consolidating laboratory networks, ensuring regulatory alignment for assay approvals, and integrating diagnostics into broader public health initiatives. These priorities shape procurement timelines and the demand for validated, interoperable solutions compatible with existing laboratory information systems.

In Europe, the Middle East & Africa, regulatory harmonization efforts and varying healthcare financing models prompt a more nuanced approach to product entry, training, and post-market surveillance. Stakeholders in these regions often balance centralized reference testing capabilities with initiatives to expand decentralized screening. Across Asia-Pacific, rapid urbanization, varied laboratory infrastructure, and aggressive public health screening programs support accelerated adoption of point-of-care and nucleic acid amplification technologies. Regional manufacturing capacity and logistics considerations further influence deployment strategies, so cross-regional partnerships and localization efforts are increasingly important to ensure continuity of supply and to meet diverse clinical needs.

Competitive strategies and partnership models that combine platform compatibility, localized production, and integrated services to strengthen reliability and adoption

Companies active in tuberculosis diagnostics are pursuing a mix of product refinement, strategic partnerships, and operational expansion to address evolving clinical and supply chain demands. Established diagnostic manufacturers continue to invest in instrument-platform compatibility, assay breadth, and service models that reduce total cost of ownership for hospital and laboratory customers. At the same time, smaller innovators are focusing on niche product enhancements, including improved sample preparation workflows, lateral flow sensitivity gains, and turnkey point-of-care solutions that require minimal operator training.

Collaborations between diagnostics firms, reagent suppliers, and logistics providers are increasingly common, as integrated offers combining instrumentation, consumables, and digital support services improve customer retention and performance predictability. Moreover, companies are emphasizing regulatory readiness and evidence generation to facilitate adoption across diverse healthcare systems. Strategic moves such as localized manufacturing partnerships, API and reagent sourcing diversification, and lifecycle support commitments are central to vendor differentiation. For procurement and clinical stakeholders, vendor selection criteria now extend beyond analytical performance to include supply chain transparency, post-market support capabilities, and the ability to rapidly validate alternative sourcing options when disruptions occur.

Practical and prioritized actions for diagnostics leaders to harden supply chains, accelerate validation of alternatives, and align evidence generation with care settings

Industry leaders should prioritize building resilient supply chains that combine near-term mitigation with long-term strategic alignment. First, diversify supplier portfolios and validate secondary sources for critical reagents and consumables to reduce single-source exposure. Second, accelerate qualification and performance verification protocols so that alternate suppliers and localized production lines can be onboarded without unnecessary delay. These operational moves should be paired with enhanced contractual protections and inventory strategies to cushion against episodic disruptions.

From a commercial and clinical perspective, leaders should invest in evidence generation targeted to specific end-user settings and sample types, focusing on real-world performance, workflow integration, and economic implications within hospitals, clinics, and reference laboratories. Additionally, pursuing collaborative agreements with regional manufacturers and logistics partners can shorten lead times and reduce tariff sensitivity. Finally, organizations should strengthen cross-functional capabilities-linking clinical affairs, regulatory, procurement, and supply chain teams-to enable rapid scenario planning and implementation of contingency actions. Taken together, these recommendations support both short-term continuity and long-term adaptability in tuberculosis diagnostic operations.

Transparent multi-method research approach combining primary expert interviews, supply chain mapping, and regulatory synthesis to deliver actionable and verifiable insights

The research approach underpinning this analysis combined multi-source data triangulation, expert interviews, and supply chain mapping to ensure robust insights. Primary qualitative inputs were obtained through structured interviews with clinical laboratory directors, procurement leads in hospital systems, and senior R&D and regulatory professionals within diagnostic firms, enabling a grounded understanding of operational priorities and validation hurdles. These insights were cross-referenced with contemporaneous regulatory guidance documents and peer-reviewed literature to validate clinical performance expectations and technology trade-offs.

Additionally, supply chain mapping exercises identified critical nodes for reagents, instrumentation, and logistics, which informed scenario assessments around tariff impacts and localized manufacturing options. Data synthesis emphasized reproducibility and traceability of assumptions, and findings were subjected to internal peer review to ensure that inferences about procurement behavior, technology adoption, and regulatory readiness were consistent with observed practices. This methodology supports actionable, evidence-based recommendations while maintaining transparency in data sources and analytic steps.

Synthesis of strategic priorities and operational imperatives to secure diagnostic continuity, clinical accuracy, and access amid evolving technological and policy pressures

In summary, the tuberculosis diagnostic environment is at an inflection point where technological progress, shifting clinical expectations, and external pressures such as trade policy converge to reshape procurement and deployment choices. Stakeholders who proactively align product strategies with end-user workflows, diversify supply chains, and invest in evidence tailored to specific settings will be best positioned to ensure diagnostic continuity and to improve clinical outcomes.

Looking ahead, durable success will depend on operational adaptability: the ability to validate alternate suppliers quickly, to integrate point-of-care solutions where clinically appropriate, and to coordinate across regulatory and procurement functions to avoid unnecessary disruption. By implementing the strategic and tactical recommendations outlined herein, clinical networks and diagnostic providers can strengthen resilience while continuing to expand access to timely and accurate tuberculosis testing.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Tuberculosis Testing Market, by Test Type

  • 8.1. Culture Test
    • 8.1.1. Liquid Culture
    • 8.1.2. Solid Culture
  • 8.2. Immunological Test
    • 8.2.1. Elisa
    • 8.2.2. Western Blot
  • 8.3. Molecular Test
    • 8.3.1. Line Probe Assay
    • 8.3.2. Pcr
  • 8.4. Rapid Diagnostic Test
    • 8.4.1. Chromatographic
    • 8.4.2. Lateral Flow

9. Tuberculosis Testing Market, by Technology

  • 9.1. Culture Based Technology
  • 9.2. Immunodiagnostic
  • 9.3. Lipoarabinomannan Assay
  • 9.4. Nucleic Acid Amplification Test

10. Tuberculosis Testing Market, by Sample Type

  • 10.1. Blood
  • 10.2. Sputum
  • 10.3. Urine

11. Tuberculosis Testing Market, by End User

  • 11.1. Clinics
  • 11.2. Hospitals
  • 11.3. Reference Laboratory

12. Tuberculosis Testing Market, by Distribution Channel

  • 12.1. Diagnostic Laboratory
  • 12.2. Hospital Pharmacy
  • 12.3. Online Pharmacy

13. Tuberculosis Testing Market, by Application

  • 13.1. Active Tuberculosis
  • 13.2. Latent Tuberculosis

14. Tuberculosis Testing Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Tuberculosis Testing Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Tuberculosis Testing Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Tuberculosis Testing Market

18. China Tuberculosis Testing Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Becton Dickinson and Company
  • 19.7. Bio-Rad Laboratories, Inc.
  • 19.8. bioMerieux SA
  • 19.9. Cepheid, Inc.
  • 19.10. Hain Lifescience GmbH
  • 19.11. QIAGEN N.V.
  • 19.12. Roche Diagnostics International Ltd
  • 19.13. Serum Institute of India
  • 19.14. Siemens Healthineers AG
  • 19.15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TUBERCULOSIS TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TUBERCULOSIS TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LIQUID CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LIQUID CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LIQUID CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SOLID CULTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SOLID CULTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SOLID CULTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ELISA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ELISA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ELISA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY WESTERN BLOT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY WESTERN BLOT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY WESTERN BLOT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LINE PROBE ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LINE PROBE ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LINE PROBE ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CHROMATOGRAPHIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CHROMATOGRAPHIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CHROMATOGRAPHIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATERAL FLOW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATERAL FLOW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATERAL FLOW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE BASED TECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE BASED TECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE BASED TECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNODIAGNOSTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNODIAGNOSTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNODIAGNOSTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LIPOARABINOMANNAN ASSAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LIPOARABINOMANNAN ASSAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LIPOARABINOMANNAN ASSAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY NUCLEIC ACID AMPLIFICATION TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SPUTUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SPUTUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY SPUTUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REFERENCE LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REFERENCE LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REFERENCE LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ACTIVE TUBERCULOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ACTIVE TUBERCULOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY ACTIVE TUBERCULOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATENT TUBERCULOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATENT TUBERCULOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY LATENT TUBERCULOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 182. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 194. GCC TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 195. GCC TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. GCC TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 197. GCC TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 198. GCC TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 199. GCC TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 200. GCC TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 201. GCC TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. GCC TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 203. GCC TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 204. GCC TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 227. G7 TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. G7 TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. G7 TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 230. G7 TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 231. G7 TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 232. G7 TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 233. G7 TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 234. G7 TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. G7 TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 236. G7 TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 237. G7 TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 238. NATO TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. NATO TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. NATO TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 241. NATO TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 242. NATO TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 243. NATO TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 244. NATO TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 245. NATO TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. NATO TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 247. NATO TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. NATO TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. GLOBAL TUBERCULOSIS TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 255. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 256. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 257. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 259. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 260. UNITED STATES TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 261. CHINA TUBERCULOSIS TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY CULTURE TEST, 2018-2032 (USD MILLION)
  • TABLE 264. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY IMMUNOLOGICAL TEST, 2018-2032 (USD MILLION)
  • TABLE 265. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY MOLECULAR TEST, 2018-2032 (USD MILLION)
  • TABLE 266. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY RAPID DIAGNOSTIC TEST, 2018-2032 (USD MILLION)
  • TABLE 267. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 269. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 270. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA TUBERCULOSIS TESTING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)